Table of Contents
1
UI - 11872774
AU - Bates AW; Baithun SI
TI -
Secondary tumours of the penis.
SO - J R Soc Med 2002 Mar;95(3):162-3
2
UI - 11927333
AU - Carver BS; Venable DD; Eastham JA
TI -
Large granular cell tumor of the penis in a 53-year-old man with
coexisting prostate cancer.
SO - Urology 2002 Apr;59(4):602
AD - Department of Urology, Louisiana State University Health Sciences
Center, Shreveport, Louisiana 71130, USA.
Granular cell tumors are soft tissue neoplasms that rarely involve the
male external genitalia. Thus far, only 7 cases of granular cell tumor
of the penis have been reported. We report a case of granular cell tumor
of the penis in a man undergoing radical retropubic prostatectomy for
organ-confined adenocarcinoma of the prostate.
3
UI - 11873122
AU - Sapozhnikov E; Zakko S; Remoroza R; Aziz K; Levine J; Shah M; Henisz AK;
TI -
Giebisch NX
Small bowel obstruction as a unique complication of squamous cell
carcinoma of the penis.
SO - J Clin Gastroenterol 2002 Mar;34(3):289-90
4
UI - 11968805
AU - Tsukamoto T; Yonese J; Kin T; Samejima T; Hasegawa Y; Fukui I; Ishikawa
TI -
Y
[Carcinoma in situ of the penis rapidly progressing after carbon dioxide
laser treatment]
SO - Nippon Hinyokika Gakkai Zasshi 2002 Mar;93(3):483-6
AD - Department of Urology, Cancer Institute Hospital.
Laser treatment is considered to be effective in treating carcinoma in
situ of the penis. We, however, report a case with carcinoma in situ of
the penis which developed invasive carcinoma and inguinal lymphnode
metastases only 6 months after the laser treatment. A 74-year-old man
with pseudophimosis presented with redness of the glans penis. A
physical examination revealed thick erythema, 12 millimeters in
diameter, around the external urethral meatus. Histologically, biopsy
revealed squamous cell carcinoma in situ. No metastasis was suspected by
physical examination and imaging studies. Although the lesion appeared
to slightly extend into the urethra, it was primarily treated with the
CO2 laser. Six months after the treatment, however, local recurrence was
confirmed by the touch smear cytology, resulting in the partial
amputation of the penis. The histopathological examination revealed
subepithelial and marked lymphatic invasion of the tumor and positive
margin in the urethral stump (squamous cell carcinoma in situ). Further,
since bilateral superficial inguinal lymphnode swelling appeared, total
amputation of the penis with perineal urethrotomy and pelvic/inguinal
lymphnode dissection was performed subsequently. The metastases to
bilateral inguinal lymphnodes were confirmed histologically. The patient
received adjuvant chemotherapy and has been alive and well without
evidence of disease 40 months after the initial treatment.
5
UI - 11907505
AU - Schroeder TL; Sengelmann RD
TI -
Squamous cell carcinoma in situ of the penis successfully treated with
imiquimod 5% cream.
SO - J Am Acad Dermatol 2002 Apr;46(4):545-8
AD - Washington University, St. Louis, MO 63141, USA.
BACKGROUND: Multiple treatments for squamous cell carcinoma in situ
(SCCIS) of the penis have been used with variable success and morbidity.
Surgery and destructive treatment modalities have significant risk of
scarring, deformity, and impaired function. OBJECTIVE: The purpose of
this study was to determine whether topical imiquimod 5% cream is a
potentially effective treatment for SCCIS of the penis and to qualify
treatment associated morbidity. METHODS: The case of a patient with
extensive penile SCCIS is reported. The patient was treated with topical
imiquimod 5%, administered daily until blistering occurred (2 cycles).
Biopsy specimens were obtained to confirm tumor clearance. RESULTS: One
month after therapy was completed, no clinical or histologic evidence of
residual tumor was found. Adverse effects of imiquimod included
localized tenderness and erythema. No evidence of scarring, deformity,
loss of function, or tumor recurrence was noted 18 months after
treatment. CONCLUSION: Imiquimod 5% cream may represent an alternative
treatment option for SCCIS of the penis.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home